Predicting Outcomes of Prostate Cancer Immunotherapy by Personalized Mathematical Models by Kronik, Natalie et al.
Predicting Outcomes of Prostate Cancer Immunotherapy
by Personalized Mathematical Models
Natalie Kronik
1¤, Yuri Kogan
1, Moran Elishmereni
1, Karin Halevi-Tobias
1, Stanimir Vuk-Pavlovic ´2.,
Zvia Agur
1*
.
1Institute for Medical BioMathematics, Bene Ataroth, Israel, 2College of Medicine, Mayo Clinic, Rochester, Minnesota, United States of America
Abstract
Background: Therapeutic vaccination against disseminated prostate cancer (PCa) is partially effective in some PCa patients.
We hypothesized that the efficacy of treatment will be enhanced by individualized vaccination regimens tailored by simple
mathematical models.
Methodology/Principal Findings: We developed a general mathematical model encompassing the basic interactions of a
vaccine, immune system and PCa cells, and validated it by the results of a clinical trial testing an allogeneic PCa whole-cell
vaccine. For model validation in the absence of any other pertinent marker, we used the clinically measured changes in
prostate-specific antigen (PSA) levels as a correlate of tumor burden. Up to 26 PSA levels measured per patient were divided
into each patient’s training set and his validation set. The training set, used for model personalization, contained the
patient’s initial sequence of PSA levels; the validation set contained his subsequent PSA data points. Personalized models
were simulated to predict changes in tumor burden and PSA levels and predictions were compared to the validation set.
The model accurately predicted PSA levels over the entire measured period in 12 of the 15 vaccination-responsive patients
(the coefficient of determination between the predicted and observed PSA values was R
2=0.972). The model could not
account for the inconsistent changes in PSA levels in 3 of the 15 responsive patients at the end of treatment. Each validated
personalized model was simulated under many hypothetical immunotherapy protocols to suggest alternative vaccination
regimens. Personalized regimens predicted to enhance the effects of therapy differed among the patients.
Conclusions/Significance: Using a few initial measurements, we constructed robust patient-specific models of PCa
immunotherapy, which were retrospectively validated by clinical trial results. Our results emphasize the potential value and
feasibility of individualized model-suggested immunotherapy protocols.
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Introduction
Prostate cancer (PCa) is the second most common malignancy
in men [1]. Primary treatment includes prostatectomy and/or
radiation therapy. If circulating levels of prostate-specific antigen
(PSA) increase after primary therapy, they indicate activation of
residual cancer that is then therapeutically controlled by androgen
deprivation. However, disseminated cancer cells often become
androgen-independent, leading to another increase in circulating
PSA levels and manifesting metastases [1]. From the observation
of the latter rise in PSA level to the appearance of symptomatic
metastases, the disease does not exert symptoms affecting physical
wellbeing. For this reason, no therapy is administered, lest the
quality of life be adversely affected by chemotherapy that is
currently used in terminal PCa [2]. Thus, the period of
asymptomatic PSA level increase has been considered appropriate
for studies testing the efficacy of immunotherapy that is usually
devoid of major adverse events.
PCa immunotherapy has begun to yield encouraging clinical
effects, though not a definitive cure [3–4]. For example, partial
responses have been induced by autologous transfer of ex vivo
activated antigen presenting cells [5–6], cytokine-secreting tumor
vaccines [7], vaccines containing recombinant proteins or nucleic
acids and other cell-based strategies targeting cancer antigens,
such as PSA or prostate-specific membrane antigen [8]. Most
recently, a treatment employing ex vivo processed autologous
antigen presenting cells combined with prostatic acid phosphatase
[9] has received regulatory approval for treatment of metastatic
PCa. In a recent phase 2 clinical study, an allogeneic PCa whole-
cell vaccine stimulated expansion of tumor-specific immune cells
in non-metastatic androgen-independent PCa patients [10]. The
treatment was safe, and the rate of PSA increase (‘‘PSA velocity’’)
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patients demonstrated a significant variability in response to
treatment, that could be due to differences in individual immune
history and tumor biology [11]. Suppressed immunity in PCa
patients could also contribute to the relative lack of efficacy of PCa
immunotherapy [12–16]. Restoring and enhancing immunity
should be a major goal of immunotherapy [17], yet the complexity
of immune system defies the attempts to achieve it. For that
reason, immunity has been often studied by mathematical
modeling.
Mathematical modeling has been a valuable tool in describing,
quantifying and predicting the behavior of complex systems. In
particular, mathematical models have played an important role in
providing non-intuitive insights into tumor growth and progression
[18–21], tumor-associated angiogenesis [22–25], and evolution of
drug resistance [26–27]. Mathematical models have been
successfully validated and applied for rational design of cancer
therapy, for optimizing efficacy while minimizing toxicity [28–32],
and for streamlining drug discovery and development [33]. More
recently, cytokine-based and cellular immunotherapy have been
modeled and scrutinized [34–44], and some models were validated
experimentally and clinically [39,45].
Differences in individual responses to PCa vaccination [10] raise
the question whether mathematical modeling can aid in predicting
the effects of immunotherapy on a single patient by quantitatively
describing the interactions of cancer and the immunotherapy-
modulated immune system. To study this question, we have
developed a simple mathematical model describing the basic time-
dependent relationships of PSA and immunity in patients treated
by the allogeneic PCa whole-cell vaccine [10]. The PSA levels
measured for each patient [10] were used to individualize and
validate our model. Although PSA has been abandoned as a
quantitative measure of PCa [46], in the absence of a more
pertinent marker we used its circulating levels as a correlate of
tumor burden and indicator of acute perturbation by therapy. By
simulating therapy outcomes following in silico treatment modifi-
cation (adjustment of the vaccine dose or administration schedule),
we have also defined the individualized treatment protocols to be
tested for more effective clinical outcomes.
Results
General mathematical model
First, we constructed a general mathematical model of the
immune response in PCa patients receiving vaccination therapy
(Fig. 1, Methods and Supplemental Material S1). The model gives
a general description of the dynamics of the disease, immune
stimulation and immune suppression. It takes into account the
time-dependent interplay of these processes, as affected by ongoing
vaccination, all determining the ultimate clinical outcome. The
model can be individualized by patient-specific parameters.
Retrospective model validation
Next, we tested the ability of the model to describe the PSA
course in the patients who initially responded to therapy (see
Methods). We used the PSA levels measured before and during the
initial five to nine treatment cycles (the total of 10–15
measurements; ‘‘training set’’) to individualize the model.
Individual models successfully predicted the PSA course during
the subsequent cycles and beyond (‘‘validation set’’) in 12 among
15 responders (Fig. 2). The predicted PSA values conformed
closely to the measured values in the validation sets (R
2=0.972).
The initial stepwise increase of the size of the training set
improved the prediction accuracy for all patients, but at some
point the improvement became negligible (Fig. 3). Prediction
accuracy as a function of the training set size followed different
patterns in different patients. For example, for Patient 3, the
prediction accuracy improved gradually and monotonically to
reach the near-best level with rather few training points (Fig. 3A,
seventh panel). In contrast, for Patient 20, a good accuracy was
achieved already at the fourth iteration with 11 training points
(Fig. 3B, fourth panel), but with more training points the accuracy
lessened until it stabilized at iteration 9.
Three patients displayed unusual and inexplicably abrupt
changes in PSA levels, or inconsistent PSA trends, towards the
end of treatment; the model could not account for this behavior
(Fig. 4). However, for these patients the overall fit during most of
the vaccination treatment was in good agreement with PSA values.
Personalizing model-guided therapy
Having validated the model, we could test the response to
modification of treatment, i.e., to the change in dose size or
administration schedule. We hypothesized that by the use of
personalized models, we can suggest treatment modifications to
stabilize PSA levels. Consequently, we simulated treatment
protocols modified either by an increased vaccine dose or decreased
intervals between vaccinations in the individually parameterized
models, for the nine patients who completed treatment.
We found that for each patient, the putative stabilization of PSA
levels required different modifications of vaccine dose or interval
between vaccinations (Table 1). For example, for Patient 14 a
moderate reduction of the interval (i.e., 21 days compared to the
standard 28 days) was predicted to suffice, while other patients
required more frequent vaccination with the standard dose
(2.4610
7 cells). Patient 20, however, required either the largest
among the considered vaccine doses (a 30-fold increase), or daily
administration of the standard dose.
To maintain the suggested regimens within clinical constraints,
we studied the effects of reducing the interval between vaccina-
tions to 14 or 21 days, or of doubling or tripling the standard dose,
and compared the predicted outcomes to the actually measured
effects of the administered standard treatment. Fig. 5 displays two
examples of such a comparison: for Patient 18, vaccinations with
the standard dose administered more often (every 21 days), or the
Figure 1. Model of interactions among the cellular vaccine (V ),
immune system and prostate cancer cells (P). Dm, antigen-
presenting dermal dendritic cells; DC, mature dendritic cells; DR,
‘‘exhausted’’ dendritic cells; R, regulatory/inhibitory cells; C, antigen-
specific effector cells (e.g., cytotoxic T cells).
doi:10.1371/journal.pone.0015482.g001
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predicted to yield similar effects on PSA levels. In Patient 21, the
same predicted effect would be induced by the standard dose
administered as frequently as every 14 days, or by the triple dose
administered every 28 days.
Discussion
Co-evolution of tumors and immunity is complex and not fully
understood. The process includes time-dependent interactions that
shape both immunity and the tumor, and determine which will
prevail. For situations when immunity prevails, we have little
information about the factors that determine the outcome; when
tumors prevail, we observe only their manifest phase although
tumor effects on immunity may have started even at the
precancerous phase [47]. The paucity of pertinent information
and the inherent complexity of the system call for mathematical
modeling to formally describe and quantify the co-development of
malignancy and immunity, and to predict strategies for additional
immune manipulation to enhance clinical outcomes. The
feasibility of this approach is rooted in the role mathematical
models have played in providing non-intuitive insights into tumor
growth, progression, and treatment.
We have developed a simple mathematical model, individual-
ized it by fitting to PSA values recorded in individual patients
before and during vaccination therapy, validated the model by
subsequent individual PSA values, and used the results to predict
the immediate response of PSA levels to modifications of vaccine
dose or administration schedule. The model was remarkably
successful in predicting PSA level changes in 12 out of 15 analyzed
treatment-responsive patients. The manifested robustness of the
fits was not compromised by the model simplicity, encompassing
no more than four patient-specific parameters, with other
parameters being derived from preclinical and clinical information
collected from disparate published sources. Apparently, a generic
representation of the interplay of immune activation and
suppression suffices to describe clinical responses without the need
to consider all individual mechanistic elements participating in
immune regulation separately.
Derivation of patient-specific parameters from training sets
and the successful validation of individualized models ascertain
the predictive power of our model. For three patients, validation
was unsuccessful because of the non-monotonous behavior of
PSA levels at the end of vaccination course. Of note, deviation of
the course of PSA levels from monotony could indicate
unpredicted significant changes in the dynamic relationships
     
       
       
Figure 2. Validation of individualized models for patients responding to vaccination. Patient-specific best-fit model parameters were
derived by fitting the model to the respective pretreatment PSA values and the initial in-treatment PSA values (red). Subsequent PSA levels (blue)
were predicted by the use of the obtained best-fit parameters. In this and subsequent figures vertical dashed lines indicate the beginning of
vaccination treatment on day 0. Achieving good predictive power required a different size of the training set for each patient. The black box
emphasizes Patient 3 whose data are analyzed in Fig. 3A; the gray box pertains to Patient 20 analyzed in Fig. 3B.
doi:10.1371/journal.pone.0015482.g002
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that this took place because vaccination broke down tumor
progression.
As responses to vaccination differed among the patients
significantly, a major motive for this study was to ascertain the
feasibility of improving individualized treatment. Having validated
the individually parameterized models of the effect of vaccination,
we tested whether the model can suggest modifications in vaccine
dose or administration schedule needed to stabilize PSA levels.
The suggested changes also differed among patients, a finding
emphasizing the potential value of testing individualized vaccina-
tion protocols in clinical trials. It is noteworthy that modifications
of either the size of vaccine dose or the interval between doses
could result in comparable tumor responses, allowing considerable
flexibility in the choice of clinically and logistically most feasible
protocols. Thus, the benefit of the method is that it could identify
the patients who will not respond to therapy and enhance
treatment efficacy for those who will.
To obtain an accurate predictive model, we found that each
patient required a different number of PSA measurements to
complete his personal training set. This raises the question whether
one can determine, during treatment, the number of measure-
ments sufficient for evaluation of personal model parameters, so
that the model can be used for individualized modification of the
     
       
       
       
       
       
Figure 3. Model calibration by increasing the size of the training set. The number of PSA measurements in the training sets (red) for Patient
3 (A) and Patient 20 (B) was gradually increased, and the fitted model predictions were compared to the PSA measurements in the validation set
(blue). TPs = training points. Boxed panels (15 TPs in A, 11 TPs in B) indicate the individually adjusted, minimal training sets that yield accurate model
predictions (also shown in boxed panels in Fig. 2).
doi:10.1371/journal.pone.0015482.g003
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algorithm by which one can determine the number of accumu-
lated measurements that suffices for completion of the training set
(Y. Kogan et al., in preparation).
The mechanistic underpinning of the model could be greatly
enhanced by the introduction of factors directly related to changes
in frequency and activity of immune cells and molecules, their
integrated effects on the tumor, as well as the effects of the tumor
on immunity. This, however, is a formidable task, as demonstrated
by numerous laboratory parameters compiled from the same
patients we analyzed in this study [10]. In our analysis, no single
immune parameter correlated with the delay of the onset of PSA
progression (an endpoint of the study); however, an artificial
intelligence analysis uncovered tenuous trends in integrated
outcomes of multiple parameters that might drive immunity into
a particular direction (e.g., towards TH1-type response [10]). This
insight opens numerous possibilities, however challenging, for
constructing and testing deterministic mathematical models of co-
evolution of tumors and immunity and studying the role of
immune manipulation for therapeutic purposes. Our model can be
employed with other biomarkers of tumor progression or other
treatment types. Its use for other cancer indications should be
examined.
In summary, we have presented and retrospectively validated a
novel personalized mathematical model of short-term effects of
vaccination on PCa. By iterative model fitting, we discovered that
only a few pretreatment and in-treatment PSA measurements
suffice to produce a predictive personalized model. The possibility
to anticipate clinical outcomes before completion of treatment
opens the door to in-treatment therapy modification to enhance
the clinical response.
Materials and Methods
Patients and treatment
We collected the de-identified data from a Phase 2 clinical trial
of an in vitro prepared allogeneic PCa whole-cell vaccine,
administered to asymptomatic nonmetastatic PCa patients, whose
circulating PSA levels were rising despite androgen suppression
(Cohort 1 in ref. [10]). Treatment included 14 intradermal
applications of the vaccine, the first two containing Bacille Calmette-
Gue ´rin (BCG). The initial three doses were spaced two weeks apart,
followed by 11 doses spaced four weeks apart, so that the
treatment period lasted approximately one year. Circulating PSA
was measured prior to treatment, at vaccine injections, and
sporadically between injections and after completion of treatment.
The number of pre-treatment, in-treatment and post-treatment
PSA measurements varied among the patients.
To classify the patients by response to treatment, we evaluated
individual PSA velocity (linear change of logarithm of PSA levels)
before therapy and during the first four cycles of therapy. In 15
patients vaccination reduced the PSA velocity, while in others it
did not. We studied the PSA data solely from the responding
patients.
General mathematical model
We modeled the basic interactions of PCa and immunity by a
system of seven ordinary differential equations accounting for
interactions of the vaccine, the immune system and cancer cells
within the skin, the lymph nodes and other tissues (disseminated
tumor cells). The model is based on the assumption that the vaccine
stimulates cancer-specific immunity, butalso that normalregulatory
 
Figure 4. Validation of individualized models for patients with non-monotonous PSA course. Best-fit model parameters for Patients 1, 9,
and 10 were obtained by fitting the model to the training set (red). Solid lines indicate the predicted subsequent directions of the PSA level change.
However, the measured PSA values indicate a drastic change in the behavior of PSA levels (blue).
doi:10.1371/journal.pone.0015482.g004
Table 1. Individualized therapy modifications predicted to
prevent tumor progression.
Patient No. Dose increase factor Administration interval (days)
32 . 5 1 5
52 . 3 1 7
73 . 2 1 6
12 2.7 16
14 1.5 21
18 2.1 18
20 27.9 1
21 5.0 12
22 5.08 12
Minimal dose increase or maximal administration interval required to prevent
in-treatment PSA elevation of more than 10 percent, analyzed for patients who
completed the treatment course.
doi:10.1371/journal.pone.0015482.t001
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fully detailed in Fig. 1 and Supplemental Material S1.
Model implementation
The model and curve-fitting algorithms were implemented on a
MATLABH programming platform (MathWorks, Natick, MA). We
solved the model equations by the numerical ordinary differential
equation solvers available in MATLAB. Fitting of the model to the
data was performed using constrained optimization procedures.
Individualized models
To individualize the model, we evaluated selected parameters
for individual patients. Most model parameters were evaluated
from published in vitro and in vivo data and were assumed to be
similar for all patients (Table 2; for details, see Supplemental
Material S1). Tumor growth rate (r), CTL killing activity (ap), as
well as A and B, the two parameters correlating tumor burden and
PSA levels, were considered patient-specific, based on the
observations that tumor growth rates, PSA secretion rates and
intensity of vaccine-induced immune response vary significantly
among individuals. To avoid over-parametrization, we attributed
the intensity of immune response to the single parameter ap.
To estimate patient-specific parameters in individual models, we
fitted the model by the least-squares method to the pertinent
‘‘training set’’ that included all pre-treatment and several initial in-
treatment PSA values for each patient; the number of training data
points could differ among the patients. Next, we used the results to
simulate the subsequent course of PSA change and compared the
simulation with PSA measurements recorded following measure-
ments in the training set (‘‘validation set’’). If prediction accuracy
was low, the size of the training set was iteratively increased by a
subsequent PSA measurement, subtracting the point from the
validation set.
Model validation
To predict PSA dynamics beyond the training set, we simulated
each individualized model under the personal vaccination
schedule (which could include minute variations from the general
     
       
Figure 5. Stabilizing PSA levels by model-aided modification of the vaccination regimen. Individualized models for Patients 18 and 21
were used to predict PSA dynamics after modification of the vaccination regimen within limits deemed clinically possible. Thin gray lines represent
the best-fit curves to PSA dynamics observed under the standard treatment regimen (2.4610
7 vaccine cells administered every 28 days; compare with
Fig. 2); thick red lines are the predicted courses of PSA levels when vaccination regimens is modified. For Patient 18, the simulated effects are shown
of the doubling of vaccine dose (4.8610
7 vaccine cells; A) or reducing the vaccination interval to 21 days (B). For Patient 21, the vaccine dose was
tripled (7.2610
7 vaccine cells; C) or vaccination interval halved (D).
doi:10.1371/journal.pone.0015482.g005
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clinically observed PSA levels in the validation set. Goodness-of-fit
was evaluated pooling together all the validation data points from
all the patients. To compare predictions with measurements, we
calculated the coefficient of determination, R
2, between the
predicted and observed PSA values.
Therapy individualization
We probed whether intensifying treatment could improve
vaccine efficacy in individual patients. Hence, based on the
validated individual models for the nine patients who completed
treatment, we simulated the effects of many intensified vaccination
protocols for each patient. Intensification included a graded 10
percent increase above the standard vaccine dose or graded one-
day reduction of administration interval relative to standard
schedule. We singled out individual vaccine administration
schedules that should lead to stabilization of PSA levels at the
end of treatment, at concentrations not more than 10 percent
above the pre-treatment level. For each patient, minimal increase
in vaccine dose and minimal reduction in dosing interval that meet
the above PSA stabilization criterion are reported in Table 1.
Supporting Information
Material S1 This file includes (a) the mathematical model of
prostate cancer therapeutic vaccination; (b) parameter estimation.
(DOCX)
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